Phosphodiesterases as targets for modulating T-cell responses.

[1]  M. Houslay.  Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. , 2010, Trends in biochemical sciences.

[2]  K. Okkenhaug,et al.  Cross Talk between Phosphatidylinositol 3-Kinase and Cyclic AMP (cAMP)-Protein Kinase A Signaling Pathways at the Level of a Protein Kinase B/β-Arrestin/cAMP Phosphodiesterase 4 Complex , 2010, Molecular and Cellular Biology.

[3]  C. Vlachopoulos,et al.  PDE5 inhibitors in non-urological conditions. , 2009, Current pharmaceutical design.

[4]  F. Martinez,et al.  Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials , 2009, The Lancet.

[5]  F. Martinez,et al.  Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials , 2009, The Lancet.

[6]  J. Barrish,et al.  Identification of potent pyrimidine inhibitors of phosphodiesterase 7 (PDE7) and their ability to inhibit T cell proliferation. , 2009, Bioorganic & medicinal chemistry letters.

[7]  Jiuhong Kang,et al.  Deficiency of a β-arrestin-2 signal complex contributes to insulin resistance , 2009, Nature.

[8]  D. Spina,et al.  PDE4 inhibitors: current status , 2008, British journal of pharmacology.

[9]  G. Prins,et al.  Perinatal exposure to oestradiol and bisphenol A alters the prostate epigenome and increases susceptibility to carcinogenesis. , 2008, Basic & clinical pharmacology & toxicology.

[10]  C. Carlson,et al.  Inhibition of T Cell Activation by Cyclic Adenosine 5′-Monophosphate Requires Lipid Raft Targeting of Protein Kinase A Type I by the A-Kinase Anchoring Protein Ezrin1 , 2007, The Journal of Immunology.

[11]  J. Beavo,et al.  Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. , 2007, Annual review of biochemistry.

[12]  V. Kuchroo,et al.  Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression , 2007, The Journal of experimental medicine.

[13]  H. Schild,et al.  Cyclic adenosine monophosphate is a key component of regulatory T cell–mediated suppression , 2007, The Journal of experimental medicine.

[14]  Y. Shimizu,et al.  Amelioration of collagen-induced arthritis in mice by a novel phosphodiesterase 7 and 4 dual inhibitor, YM-393059. , 2007, European journal of pharmacology.

[15]  R. Lefkowitz,et al.  β-Arrestins and Cell Signaling , 2007 .

[16]  Vincent C. Manganiello,et al.  Foxp3-dependent programme of regulatory T-cell differentiation , 2007, Nature.

[17]  H. Ke,et al.  Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity. , 2007, Current topics in medicinal chemistry.

[18]  E. Degerman,et al.  Re-discovering PDE3 inhibitors--new opportunities for a long neglected target. , 2007, Current topics in medicinal chemistry.

[19]  Shimon Sakaguchi,et al.  Foxp3+CD25+CD4+ natural regulatory T cells in dominant self‐tolerance and autoimmune disease , 2006, Immunological reviews.

[20]  B. Rouse,et al.  Regulatory T cells in virus infections , 2006, Immunological reviews.

[21]  M. Beyer,et al.  Regulatory T cells in cancer. , 2006, Blood.

[22]  E. Aandahl,et al.  FOXP3+CD4+CD25+ Adaptive Regulatory T Cells Express Cyclooxygenase-2 and Suppress Effector T Cells by a Prostaglandin E2-Dependent Mechanism1 , 2006, The Journal of Immunology.

[23]  E. Aandahl,et al.  Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment , 2006, AIDS.

[24]  Jennifer E. Chubb,et al.  DISC1 and PDE4B Are Interacting Genetic Factors in Schizophrenia That Regulate cAMP Signaling , 2005, Science.

[25]  Kam Y. J. Zhang,et al.  Keynote review: phosphodiesterase-4 as a therapeutic target. , 2005, Drug discovery today.

[26]  J. Corbin,et al.  Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction. , 2005, The Urologic clinics of North America.

[27]  G. Baillie,et al.  RNA Silencing Identifies PDE4D5 as the Functionally Relevant cAMP Phosphodiesterase Interacting with βArrestin to Control the Protein Kinase A/AKAP79-mediated Switching of the β2-Adrenergic Receptor to Activation of ERK in HEK293B2 Cells* , 2005, Journal of Biological Chemistry.

[28]  M. Houslay,et al.  In resting COS1 cells a dominant negative approach shows that specific, anchored PDE4 cAMP phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of AKAP-tethered protein kinase A type II located in the centrosomal region. , 2005, Cellular signalling.

[29]  S. Jin,et al.  Specific Role of Phosphodiesterase 4B in Lipopolysaccharide-Induced Signaling in Mouse Macrophages 1 , 2005, The Journal of Immunology.

[30]  T. Sotnikova,et al.  An Akt/β-Arrestin 2/PP2A Signaling Complex Mediates Dopaminergic Neurotransmission and Behavior , 2005, Cell.

[31]  J. Scott,et al.  Compartmentalisation of phosphodiesterases and protein kinase A: opposites attract , 2005, FEBS letters.

[32]  A. Nicholson,et al.  Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a Selective Inhibitor of Phosphodiesterase 7: In Vitro Studies in Human Monocytes, Lung Macrophages, and CD8+ T-Lymphocytes , 2004, Molecular Pharmacology.

[33]  M. Zaccolo,et al.  TCR- and CD28-Mediated Recruitment of Phosphodiesterase 4 to Lipid Rafts Potentiates TCR Signaling1 , 2004, The Journal of Immunology.

[34]  Chengyu Liu,et al.  Cyclic nucleotide phosphodiesterase 3A-deficient mice as a model of female infertility. , 2004, The Journal of clinical investigation.

[35]  S. Sakaguchi.  Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. , 2004, Annual review of immunology.

[36]  D. Nixon,et al.  Human CD4+ CD25+ Regulatory T Cells Control T-Cell Responses to Human Immunodeficiency Virus and Cytomegalovirus Antigens , 2004, Journal of Virology.

[37]  K. Taskén,et al.  Cytokine networks are pre-activated in T cells from HIV-infected patients on HAART and are under the control of cAMP , 2004, AIDS.

[38]  T. Kohout,et al.  β-Arrestin1 Mediates Insulin-like Growth Factor 1 (IGF-1) Activation of Phosphatidylinositol 3-Kinase (PI3K) and Anti-apoptosis* , 2003, Journal of Biological Chemistry.

[39]  K. McIntyre,et al.  Phosphodiesterase 7A-Deficient Mice Have Functional T Cells , 2003, The Journal of Immunology.

[40]  G. Baillie,et al.  The Unique Amino-terminal Region of the PDE4D5 cAMP Phosphodiesterase Isoform Confers Preferential Interaction with β-Arrestins* , 2003, Journal of Biological Chemistry.

[41]  W. N. Zagotta,et al.  Cyclic nucleotide-gated ion channels. , 2003, Annual review of cell and developmental biology.

[42]  John D. Scott,et al.  AKAP mediated signal transduction. , 2003, Annual review of pharmacology and toxicology.

[43]  N. C. Price,et al.  Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change. , 2003, The Biochemical journal.

[44]  J. Madrenas,et al.  Regulation of T-Cell Activation by Phosphodiesterase 4B2 Requires Its Dynamic Redistribution during Immunological Synapse Formation , 2003, Molecular and Cellular Biology.

[45]  Mark Gurney,et al.  The gene encoding phosphodiesterase 4D confers risk of ischemic stroke , 2003, Nature Genetics.

[46]  E. Aandahl,et al.  Impaired Secretion of IL-10 by T Cells from Patients with Common Variable Immunodeficiency–Involvement of Protein Kinase A Type I1 , 2003, The Journal of Immunology.

[47]  K. Taskén,et al.  Combined Spatial and Enzymatic Regulation of Csk by cAMP and Protein Kinase A Inhibits T Cell Receptor Signaling* , 2003, The Journal of Biological Chemistry.

[48]  H. Manji,et al.  Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for Difficult-to-Treat depression , 2003, Biological Psychiatry.

[49]  A. Weiss,et al.  The PI‐3 kinase/Akt pathway and T cell activation: pleiotropic pathways downstream of PIP3 , 2003, Immunological reviews.

[50]  O. Acuto,et al.  Molecular modifiers of T cell antigen receptor triggering threshold: the mechanism of CD28 costimulatory receptor , 2003, Immunological reviews.

[51]  V. Horejsi,et al.  Phosphorylation-Dependent Regulation of T-Cell Activation by PAG/Cbp, a Lipid Raft-Associated Transmembrane Adaptor , 2003, Molecular and Cellular Biology.

[52]  Jeffrey A. Bluestone,et al.  Opinion-regulatory lymphocytes: Natural versus adaptive regulatory T cells , 2003, Nature Reviews Immunology.

[53]  M. Houslay,et al.  PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. , 2003, The Biochemical journal.

[54]  G. Koretzky,et al.  Adaptors as central mediators of signal transduction in immune cells , 2003, Nature Immunology.

[55]  P. Barnes,et al.  Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[56]  R. Lefkowitz,et al.  Retraction for Baillie et al., β-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates β-adrenoceptor switching from Gs to Gi , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[57]  D. Spina.  Theophylline and PDE4 inhibitors in asthma , 2003, Current opinion in pulmonary medicine.

[58]  T. Kohout,et al.  Targeting of Cyclic AMP Degradation to β2-Adrenergic Receptors by β-Arrestins , 2002, Science.

[59]  Ash A. Alizadeh,et al.  Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[60]  D. Webb,et al.  Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. , 2002, Urology.

[61]  D. Nixon,et al.  Inhibition of Antigen-Specific T Cell Proliferation and Cytokine Production by Protein Kinase A Type I1 , 2002, The Journal of Immunology.

[62]  A. Feldman,et al.  Reevaluating the role of phosphodiesterase inhibitors in the treatment of cardiovascular disease , 2002, Clinical cardiology.

[63]  S. Jin,et al.  Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[64]  L. Appleman,et al.  CD28 Costimulation Mediates Down-Regulation of p27kip1 and Cell Cycle Progression by Activation of the PI3K/PKB Signaling Pathway in Primary Human T Cells1 , 2002, The Journal of Immunology.

[65]  Tullio Pozzan,et al.  Discrete Microdomains with High Concentration of cAMP in Stimulated Rat Neonatal Cardiac Myocytes , 2002, Science.

[66]  John D. Scott,et al.  Signaling Complexes: Junctions on the Intracellular Information Super Highway , 2002, Current Biology.

[67]  U. Kaupp,et al.  Cyclic nucleotide-gated ion channels. , 2002, Physiological reviews.

[68]  S. Jin,et al.  Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling , 2002, Trends in Endocrinology & Metabolism.

[69]  O. Acuto,et al.  CD28 as a molecular amplifier extending TCR ligation and signaling capabilities. , 2001, Immunity.

[70]  M. Fresno,et al.  Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation. , 2001, The Journal of pharmacology and experimental therapeutics.

[71]  R. Lechler,et al.  Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. , 2001, Blood.

[72]  D. Essayan.  Cyclic nucleotide phosphodiesterases. , 2001, The Journal of allergy and clinical immunology.

[73]  Sheraz Yaqub,et al.  Release from Tonic Inhibition of T Cell Activation through Transient Displacement of C-terminal Src Kinase (Csk) from Lipid Rafts* , 2001, The Journal of Biological Chemistry.

[74]  Sayuri Yamazaki,et al.  Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance , 2001, Immunological reviews.

[75]  J. Beavo,et al.  T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[76]  P. Oh,et al.  Segregation of heterotrimeric G proteins in cell surface microdomains. G(q) binds caveolin to concentrate in caveolae, whereas G(i) and G(s) target lipid rafts by default. , 2001, Molecular biology of the cell.

[77]  Tomas Mustelin,et al.  Activation of the Cooh-Terminal Src Kinase (Csk) by Camp-Dependent Protein Kinase Inhibits Signaling through the T Cell Receptor , 2001, The Journal of experimental medicine.

[78]  J. Beavo,et al.  Cloning and characterization of two splice variants of human phosphodiesterase 11A. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[79]  S. Jin,et al.  Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[80]  M. Fidock,et al.  Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase. , 2000, Biochemical and biophysical research communications.

[81]  Karel Drbal,et al.  Phosphoprotein Associated with Glycosphingolipid-Enriched Microdomains (Pag), a Novel Ubiquitously Expressed Transmembrane Adaptor Protein, Binds the Protein Tyrosine Kinase Csk and Is Involved in Regulation of T Cell Activation , 2000, The Journal of experimental medicine.

[82]  Toshifumi Takao,et al.  Transmembrane phosphoprotein Cbp regulates the activities of Src-family tyrosine kinases , 2000, Nature.

[83]  E. Aandahl,et al.  Additive effects of IL-2 and protein kinase A type I antagonist on function of T cells from HIV-infected patients on HAART. , 1999, AIDS.

[84]  W. P. Kuo,et al.  Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[85]  Paul M. Allen,et al.  Proline Residues in Cd28 and the Src Homology (Sh)3 Domain of Lck Are Required for T Cell Costimulation , 1999, The Journal of experimental medicine.

[86]  R. Wange,et al.  Specific CD3 epsilon association of a phosphodiesterase 4B isoform determines its selective tyrosine phosphorylation after CD3 ligation. , 1999, Journal of immunology.

[87]  J. Beavo,et al.  CD3- and CD28-dependent induction of PDE7 required for T cell activation. , 1999, Science.

[88]  E. Aandahl,et al.  Increased activation of protein kinase A type I contributes to the T cell deficiency in common variable immunodeficiency. , 1999, Journal of immunology.

[89]  C. Rudd.  Adaptors and Molecular Scaffolds in Immune Cell Signaling , 1999, Cell.

[90]  A M Graybiel,et al.  A family of cAMP-binding proteins that directly activate Rap1. , 1998, Science.

[91]  A. Wittinghofer,et al.  Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP , 1998, Nature.

[92]  J. Chauvin,et al.  Engagement of T cell receptor triggers its recruitment to low‐density detergent‐insoluble membrane domains , 1998, The EMBO journal.

[93]  K. Okkenhaug,et al.  Grb2 Forms an Inducible Protein Complex with CD28 through a Src Homology 3 Domain-Proline Interaction* , 1998, The Journal of Biological Chemistry.

[94]  E. Aandahl,et al.  Protein kinase A type I antagonist restores immune responses of T cells from HIV‐infected patients , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[95]  R. Xavier,et al.  Membrane compartmentation is required for efficient T cell activation. , 1998, Immunity.

[96]  L. Samelson,et al.  LAT The ZAP-70 Tyrosine Kinase Substrate that Links T Cell Receptor to Cellular Activation , 1998, Cell.

[97]  Mary J. Tharayil,et al.  Growth Factor Receptor-bound Protein 2 SH2/SH3 Domain Binding to CD28 and Its Role in Co-signaling* , 1998, The Journal of Biological Chemistry.

[98]  Hiroto Yamaguchi,et al.  Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation , 1996, Nature.

[99]  J. Beavo,et al.  Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[100]  P. Barnes,et al.  Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T‐lymphocytes: role in regulating proliferation and the biosynthesis of interleukin‐2 , 1996, British journal of pharmacology.

[101]  C. Rudd,et al.  p56Lck and p59Fyn regulate CD28 binding to phosphatidylinositol 3-kinase, growth factor receptor-bound protein GRB-2, and T cell-specific protein-tyrosine kinase ITK: implications for T-cell costimulation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[102]  D. Olive,et al.  Binding of phosphatidyl-inositol-3-OH kinase to CD28 is required for T-cell signalling , 1994, Nature.

[103]  L. Cantley,et al.  T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[104]  S. Døskeland,et al.  Cyclic AMP-dependent protein kinase type I mediates the inhibitory effects of 3',5'-cyclic adenosine monophosphate on cell replication in human T lymphocytes. , 1992, The Journal of biological chemistry.

[105]  J. Partanen,et al.  The human p50csk tyrosine kinase phosphorylates p56lck at Tyr‐505 and down regulates its catalytic activity. , 1992, The EMBO journal.

[106]  M. Okada,et al.  A protein tyrosine kinase involved in regulation of pp60c-src function. , 1989, The Journal of biological chemistry.

[107]  P. Rabinovitch,et al.  Antibody binding to CD5 (Tp67) and Tp44 T cell surface molecules: effects on cyclic nucleotides, cytoplasmic free calcium, and cAMP-mediated suppression. , 1986, Journal of immunology.

[108]  E. Krebs,et al.  An adenosine 3',5'-monophosphate-dependant protein kinase from rabbit skeletal muscle. , 1968, The Journal of biological chemistry.

[109]  D. Schadendorf,et al.  Distinct metabolism of cyclic adenosine monophosphate in regulatory and helper CD4+ T cells. , 2010, Molecular immunology.

[110]  K. Okkenhaug,et al.  Cross-talk between PI3-kinase and cAMP-Protein Kinase signaling pathways at the level of a Protein Kinase B / -arrestin / cAMP phosphodiesterase-4 complex , 2010 .

[111]  T. Nakatsuka,et al.  Effect of phosphodiesterase 7 inhibitor ASB16165 on development and function of cytotoxic T lymphocyte. , 2009, International immunopharmacology.

[112]  K. Taskén,et al.  Role for the cAMP-protein kinase A signaling pathway in suppression of antitumor immune responses by regulatory T cells. , 2008, Critical reviews in oncogenesis.

[113]  M. Giembycz.  Phosphodiesterase-4: selective and dual-specificity inhibitors for the therapy of chronic obstructive pulmonary disease. , 2005, Proceedings of the American Thoracic Society.

[114]  E. Aandahl,et al.  Localized effects of cAMP mediated by distinct routes of protein kinase A. , 2004, Physiological reviews.

[115]  K. Torgersen,et al.  Molecular mechanisms for protein kinase A-mediated modulation of immune function. , 2002, Cellular signalling.

[116]  J. Hanoune,et al.  Regulation and role of adenylyl cyclase isoforms. , 2001, Annual review of pharmacology and toxicology.

[117]  M. Conti,et al.  The molecular biology of cyclic nucleotide phosphodiesterases. , 1999, Progress in nucleic acid research and molecular biology.

[118]  M. Houslay,et al.  Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant. , 1997, The Biochemical journal.

[119]  M. Raab.  p56^ and p59^ regulate CD28 binding to phosphatidylinositol 3-kinase, growth factor receptor binding protein GRB-2 and T cell specific kinase ITK: implications for T cell co-stimulation. , 1995 .